Atophylline: from bench to market

Greenpharma is delighted to share our positive clinical results with Atophylline on atopic dermatitis. It is a first-in-class neutraligand targeting the chemokine CCL17.

This is an achievement from several years of intensive R&D initiated with our partners from the University of Strasbourg. It started with target validation, in silico scsreening, in vitro validation and now clinical studies.

 

Related articles:

• A strategy to discover decoy chemokine ligands with an anti-inflammatory activity. doi: 10.1038/srep14746.
• Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis. doi: 10.1111/ics.12948.